This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation; cancer	C-type lectin domain family 9, member A (CLEC9A; DNGR1)	Studies in cell culture and in mice suggest that agonizing DNGR1 could help lower inflammation-inducing necrosis associated with some cancer therapies. In mouse embryonic fibroblasts, knockout of <i>Dngr1</i> decreased cross-presentation of necrosis-associated antigens compared with that seen in wild-type fibroblasts. The immunogenicity of necrotic cells from the <i>Dngr1</i> knockout mice was lower than that seen in cells from wild-type littermates. Next steps include further elucidation of the functions of the DNGR1 receptor.	Patent cooperation treaty patent application filed; available for licensing	Sancho, D. <i>et al. Nat. Genet.</i> ; published online Feb. 15, 2009; doi:10.1038/nature07750 Contact: Caetano Reis e Sousa, Cancer Research UK, London Research Institute, London, U.K. e-mail: caetano@cancer.org.uk
SciBX 2(8); doi:10.1038/scibx.2009.323 Published online Feb. 26, 2009				